NCT00066443 - Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2003

Primary Completion Date

January 6, 2010

Study Completion Date

January 16, 2014

Conditions

Breast Cancer

Interventions

BIOLOGICAL

pegfilgrastim

Dose escalation schedule A\&B = 6mg fixed dose once per cycle on day 2

DRUG

docetaxel

Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2

DRUG

epirubicin hydrochloride

Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV

Trial Locations (5)

CancerCare Manitoba, Winnipeg

Atlantic Health Sciences Corporation, Saint John

Odette Cancer Centre, Toronto

Univ. Health Network-Princess Margaret Hospital, Toronto

CHA-Hopital Du St-Sacrement, Québec